STOCK TITAN

Intellia Therape reported $67.7M in revenue and a $412.7M net loss for fiscal 2025. See the full NTLA financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Intellia will webcast its September 14, 2026 Morgan Stanley healthcare conference presentation with a replay available for about three months.

(Neutral)
(Neutral)
Tags

Intellia Therapeutics (NTLA) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET.

A live webcast will be accessible via the Events and Presentations page in the Investors & Media section of Intellia’s website, with a replay available for approximately 90 days.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

Insiders sold 38,104 shares during the platform's 90-day window, which recorded net selling. That co...
Analysis

Insiders sold 38,104 shares during the platform's 90-day window, which recorded net selling. That context adds a governance signal to the conference presentation; investors could watch subsequent disclosures for operational or financing updates.

Key Figures

Conference edition: 24th annual Presentation date: September 14, 2026 Presentation time: 4:05 p.m. ET +1 more
4 metrics
Conference edition 24th annual Morgan Stanley Global Healthcare Conference
Presentation date September 14, 2026 Morgan Stanley Global Healthcare Conference
Presentation time 4:05 p.m. ET September 14, 2026 presentation
Replay availability approximately 90 days Webcast replay on Intellia's website

Historical Context

5 past events · Latest: Aug 07 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 07 Inducement grants Neutral +0.7% Eight employees received inducement restricted stock units totaling 38,200 shares.
Aug 06 Quarterly earnings Positive +2.5% Q2 results included positive Phase 3 HAELO data and 2028 cash runway.
Jul 30 Conference scheduling Neutral +2.7% Scheduled conference call and webcast to discuss second-quarter results and business updates.
Jul 06 Inducement grants Neutral -2.3% Thirteen employees received inducement restricted stock units totaling 53,250 shares.
Jun 05 Inducement grants Neutral -0.4% Six employees received inducement restricted stock units totaling 47,150 shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

NTLA showed a positive response to its recent earnings release but mixed reactions to conference scheduling and inducement-grant announcements.

Key Terms

crispr
1 terms
crispr technical
"focused on revolutionizing medicine leveraging CRISPR gene editing"
CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.

A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com


FAQ

When will Intellia Therapeutics (NTLA) present at the Morgan Stanley 24th Annual Global Healthcare Conference?

Intellia Therapeutics (NTLA) is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET.

How can investors access the live webcast of Intellia Therapeutics (NTLA) at the Morgan Stanley conference?

A live webcast of Intellia Therapeutics’ presentation will be available on the Events and Presentations page in the Investors & Media section of the company’s website at www.intelliatx.com.

Will a replay be available for Intellia Therapeutics (NTLA) Morgan Stanley conference webcast?

Yes. A replay of Intellia Therapeutics’ webcast from the Morgan Stanley 24th Annual Global Healthcare Conference will be available on the company’s website for approximately 90 days.